Literature DB >> 11773377

The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles.

Barbara Müller1, Tilo Patschinsky, Hans-Georg Kräusslich.   

Abstract

The Gag-derived protein p6 of human immunodeficiency virus type 1 (HIV-1) plays a crucial role in the release of virions from the membranes of infected cells. It is presumed that p6 and functionally related proteins from other viruses act as adapters, recruiting cellular factors to the budding site. This interaction is mediated by so-called late domains within the viral proteins. Previous studies had suggested that virus release from the plasma membrane shares elements with the cellular endocytosis machinery. Since protein phosphorylation is known to be a regulatory mechanism in these processes, we have investigated the phosphorylation of HIV-1 structural proteins. Here we show that p6 is the major phosphoprotein of HIV-1 particles. After metabolic labeling of infected cells with [ortho-32P]phosphate, we found that phosphorylated p6 from infected cells and from virus particles consisted of several forms, suggesting differential phosphorylation at multiple sites. Apparently, phosphorylation occurred shortly before or after the release of p6 from Gag and involved only a minor fraction of the total virion-associated p6 molecules. Phosphoamino acid analysis indicated phosphorylation at Ser and Thr, as well as a trace of Tyr phosphorylation, supporting the conclusion that multiple phosphorylation events do occur. In vitro experiments using purified virus revealed that endogenous or exogenously added p6 was efficiently phosphorylated by virion-associated cellular kinase(s). Inhibition experiments suggested that a cyclin-dependent kinase or a related kinase, most likely ERK2, was involved in p6 phosphorylation by virion-associated enzymes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773377      PMCID: PMC135845          DOI: 10.1128/jvi.76.3.1015-1024.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  Differential effects of protein kinase C on the levels of epithelial Na+ channel subunit proteins.

Authors:  J D Stockand; H F Bao; J Schenck; B Malik; P Middleton; L E Schlanger; D C Eaton
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

3.  Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1.

Authors:  R Welker; H Hohenberg; U Tessmer; C Huckhagel; H G Kräusslich
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses.

Authors:  B Yuan; S Campbell; E Bacharach; A Rein; S P Goff
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication.

Authors:  T D Nelle; M F Verderame; J Leis; J W Wills
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells.

Authors:  B Müller; U Tessmer; U Schubert; H G Kräusslich
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Phosphorylation of human immunodeficiency virus type 1 Vpr regulates cell cycle arrest.

Authors:  Y Zhou; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus.

Authors:  D E Ott; L V Coren; T D Copeland; B P Kane; D G Johnson; R C Sowder; Y Yoshinaka; S Oroszlan; L O Arthur; L E Henderson
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA.

Authors:  A G Bukrinskaya; A Ghorpade; N K Heinzinger; T E Smithgall; R E Lewis; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 10.  Transcriptional regulation by MAP kinases.

Authors:  R J Davis
Journal:  Mol Reprod Dev       Date:  1995-12       Impact factor: 2.609

View more
  27 in total

Review 1.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Authors:  Cagan Gurer; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 4.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

5.  Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?

Authors:  Tulio de Oliveira; Susan Engelbrecht; Estrelita Janse van Rensburg; Michelle Gordon; Karen Bishop; Jan zur Megede; Susan W Barnett; Sharon Cassol
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Human immunodeficiency virus type 2 Gag interacts specifically with PRP4, a serine-threonine kinase, and inhibits phosphorylation of splicing factor SF2.

Authors:  Erin M Bennett; Andrew M L Lever; Jane F Allen
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Comprehensive mutational analysis reveals p6Gag phosphorylation to be dispensable for HIV-1 morphogenesis and replication.

Authors:  Benjamin Radestock; Ivonne Morales; Sheikh Abdul Rahman; Sonja Radau; Bärbel Glass; René Peiman Zahedi; Barbara Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

8.  Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.

Authors:  Akinyemi I Ojesina; Beth Chaplin; Jean-Louis Sankalé; Robert Murphy; Emmanuel Idigbe; Isaac Adewole; Ernest Ekong; John Idoko; Phyllis J Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

9.  Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein.

Authors:  Alok Sharma; Karsten Bruns; René Röder; Peter Henklein; Jörg Votteler; Victor Wray; Ulrich Schubert
Journal:  BMC Struct Biol       Date:  2009-12-17

10.  Influence of calcium/calmodulin on budding of Ebola VLPs: implications for the involvement of the Ras/Raf/MEK/ERK pathway.

Authors:  Ziying Han; Ronald N Harty
Journal:  Virus Genes       Date:  2007-06-15       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.